Swedish clinical-stage diabetes company Diamyd Medical (STO:DMYD-B) announced on Tuesday that it has received positive feedback from the US Food and Drug Administration (FDA) about an Accelerated Approval pathway for its immunotherapy, Diamyd, targeting Stage 3 Type 1 Diabetes patients with the HLA DR3-DQ2 genotype.
During a recent Type C Meeting, the FDA agreed that C-peptide could be used as a surrogate endpoint to predict the clinical benefit of preserving endogenous insulin production. This acknowledgment opens the possibility for Accelerated Approval based on significant treatment-related improvements in C-peptide levels due to Diamyd administration.
Ongoing discussions between Diamyd Medical and the FDA will clarify the requirements for a Biologics License Application (BLA) under this pathway, including an earlier readout from the ongoing Phase 3 DIAGNODE-3 trial.
Diamyd Medical focuses on precision medicine therapies for Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd has received Orphan Drug Designation and Fast Track Designation from the FDA for treating Stage 1, 2, and 3 Type 1 Diabetes.
The DIAGNODE-3 Phase III trial is currently recruiting patients with recent-onset Stage 3 Type 1 Diabetes in the US and eight European countries.
Dragonfly Therapeutics names new chief financial officer
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
BioSenic expands US patent portfolio for ATO use in sepsis treatment
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP